Comparison · NCT00537095-6493d314
ZD6474 vs PLACEBO: Time to Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZD6474 vs PLACEBO: Time to Death. Trial comparisons, record NCT00537095-6493d314. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00537095-6493d314
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.264 | 0.176 | 0.376 | wilson | |
| Risk in group 2 | 0.288 | 0.197 | 0.4 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0238 | -0.166 | 0.121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.917 | 0.541 | 1.56 | log | |
| Odds ratio, group 1 over group 2 | 0.888 | 0.428 | 1.84 | log | |
| Number needed to treat, for one fewer participant with the outcome on ZD6474 than on PLACEBO | 42 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZD6474 | ZD6474, Vandetanib 300mg | 19 | 72 | OG000 |
| Group 2 | PLACEBO | PLACEBO | 21 | 73 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Time to Death
- Description
- Interim analysis time to date of randomization to date of death (data not mature at the time of this analysis, so number of deaths displayed instead.
- Time frame
- time from randomization to date of death
- Population
- For the efficacy part, 72 were randomized to received ZD6474 and 73 placebo. For the safety part, 73 patients received at least one dose of ZD6474 and 72 placebo
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
- NCT number
- NCT00537095
- Phases
- PHASE2
- Conditions
- Thyroid Neoplasms
- Interventions
- Vandetanib, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00537095?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00537095-6493d314